Navigation Links
Depomed Reports Second Quarter 2014 Financial Results

NEWARK, Calif., Aug. 6, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today reported financial results for the quarter ended June 30, 2014.

Second Quarter 2014 Summary

  • Total product sales of $28.2 million increased 100% compared to $14.1 million for the second quarter of 2013, and increased 31% from $21.5 million for the first quarter of 2014
  • Gralise® (gabapentin) product sales of $15.1 million increased 39% from $10.9 million for the first quarter of 2014 and 76% compared to $8.6 million for the second quarter of 2013
  • Zipsor® (diclofenac potassium) product sales of $6.8 million increased 28% from $5.3 million for the first quarter of 2014 and 21% compared to $5.6 million for the second quarter of 2013
  • Cambia® (diclofenac potassium for oral solution) product sales of $5.0 million increased 9% from $4.6 million for the first quarter of 2014
  • Lazanda® (fentanyl) Nasal Spray product sales of $1.4 million increased 100% from $0.7 million for the first quarter of 2014
  • Gralise added to tier 2 formulary at Catamaran, the 3rd largest PBM. Gralise is now tier 2 with the top 3 PBMs
  • Received a total of $15 million in milestone payments from Mallinckrodt during the quarter, which included a $10 million FDA approval milestone for Xartemis XR® (recognized as revenue in the first quarter of 2014) and a $5 million milestone upon FDA acceptance of the NDA filing for MNK-155 (recognized as revenue in the second quarter of 2014)
  • Generated second quarter 2014 GAAP net income of $12.7 million or $0.21 per diluted share
  • Generated second quarter 2014 non-GAAP adjusted earnings of $0.3 million or $0.01 per diluted share
  • $223.7 million of cash and marketable securities and no debt outstanding as of June 30, 2014, an increase of $10.6 million for the quarter
  • Completed bench trial in ANDA litigation related to Gralise with a ruling expected in short order
  • Srinivas G. Rao, MD, PhD, joined Depomed in July as Chief Medical Officer and announced that R. Scott Shively will join the company as Chief Commercial Officer in September
  • "Gralise and our recent acquisitions, CAMBIA and Lazanda, led the way to a strong quarter, doubling our net product sales over the same period last year.  All four of our products showed prescription growth in Q2 compared to Q1 2014," said Jim Schoeneck, President and Chief Executive Officer of Depomed.  "We believe the growth of our product revenues in Q2 and the integration of new products into our commercial organization demonstrate our ability to build a growth-oriented specialty pharmaceutical company focused on pain and central nervous system disorders. We are also thrilled to add Srini and Scott to our leadership team, increasing our depth and expertise in the pain and CNS markets.  For the remainder of 2014, we are focused on growing product revenues, acquiring additional assets that will enhance our product portfolio and managing expenses to continue to operate at positive cash flow."

    Accounting Treatment for the Sale of Type 2 Diabetes Royalty and Milestone Interests to PDLIn October 2013, Depomed sold interests in future royalty and milestone payments in the Type 2 diabetes therapeutic area to PDL Biopharma, Inc. (PDL) for $240.5 million. As a result of ongoing supply order obligations with respect to the underlying royalties, Depomed is accounting for this transaction under the debt accounting method. Although the royalty and milestone payments were sold to PDL, debt accounting requires the Company to continue to recognize the underlying royalties and milestones as revenue and record the proceeds of $240.5 million as a liability. As royalties and milestones are recognized under this arrangement, the liability is reduced and an implied non-cash interest expense is recognized.

    During the three and six months ended June 30, 2014, Depomed recognized $33.3 million and $76.1 million, respectively, of non-cash revenues, $4.9 million and $10.3 million, respectively, in non-cash interest expense and $8.3 million and  $20.1 million, respectively, in non-cash tax expense related to this arrangement.

    Second Quarter 2014 Financial ResultsTotal revenues for the second quarter of 2014 increased to $67.7 million from $30.0 million for the second quarter of 2013. A summary of total revenues for the first quarter of 2014 as compared to the corresponding prior period is as follows:Three Months Ended Six Months Ended June 30,June 30,2014201320142013(Unaudited)(Unaudited)(Unaudited)(Unaudited)Product sales:Gralise





    14,643Zipsor6,8225,55212,1658,592CAMBIA (1)4,958-9,582-Lazanda (1)1,354-2,034-Total product sales 28,24514,10649,75123,235Royalties:Glumetza US





    27,481Other4309049251,697Total royalty revenue43015,09792529,178License and other revenue:Mallinckrodt





    -Janssen---2,204Glumetza7607601,5201,520Other--1,000-Total license and other revenue5,76076017,5203,724Non-cash PDL royalty revenue





    -Total revenues (GAAP Basis)$




    Depomed acquired Lazanda in July 2013 and CAMBIA in December 2013.Selling, general and administrative expense was $32.6 million for the second quarter of 2014 as compared to $25.4 million for the second quarter of 2013. The increase in 2014 is primarily due to increased sales and marketing expenses associated with the Cambia and Lazanda® product acquisitions which occurred in the second half of 2013 and increased legal expense related to ongoing patent infringement litigation.

    Research and development expense was $1.4 million for the second quarter of 2014 as compared to $1.4 million for the second quarter of 2013.

    GAAP net income for the second quarter of 2014 was $12.7 million, or $0.21 per diluted share, compared to GAAP net income of $0.5 million, or $0.01 per diluted share for the second quarter of 2013.  The increase in GAAP net income resulted primarily from increased product sales and the recognition of non-cash revenue relating to the royalties sold to PDL as described above under the caption "Accounting Treatment for the Sale of Type 2 Diabetes Royalties and Milestones to PDL."

    Cash and marketable securities were $223.7 million as of June 30, 2014 as compared to $213.1 million as of March 31, 2014. The increase in cash and marketable securities in the second quarter of 2014 is primarily related to receipt of $15 million in milestone payments from Mallinckrodt during the second quarter of 2014.

    2014 Financial Outlook Depomed is increasing its guidance for total revenues and GAAP earnings per share  for full year 2014 and is reiterating its guidance for product sales, non-GAAP adjusted earnings per share and cash flow for  full year 2014:

  • Product sales of approximately $115 to $125 million
  • Total revenues of approximately $215 to $230 million, which includes non-cash revenues related to the PDL transaction and $15 million in milestones already received in 2014 from Mallinckrodt
  • GAAP earnings per share of approximately $0.36 to $0.51 per share, which includes the non-cash PDL revenues and non-cash PDL interest expense
  • Non-GAAP adjusted earnings per share of break-even to $0.16 per share
  • Cash flow of at least break-even excluding payment of approximately $58 million in taxes in the first quarter of 2014 related to fiscal year 2013
  • The increases in guidance regarding total revenues and GAAP earnings per share are entirely due to increased estimates of non-cash PDL royalty revenues resulting from net sales of Glumetza by Salix Pharmaceuticals during the first half of 2014.

    Non-GAAP Financial MeasuresIn this press release, Depomed includes information about non-GAAP adjusted earnings per share, a non-GAAP financial measure, as a useful operating metric for the three and six month periods ended June 30, 2014 and its 2014 financial outlook. The Company believes that the presentation of this non-GAAP financial measure, when viewed with our results and projections under GAAP and the accompanying reconciliation, provides supplementary information to investors. The Company uses this non-GAAP measure in connection with its own planning and forecasting purposes and for measuring the Company's performance. This non-GAAP financial measure should be considered in addition to, and not a substitute for, or superior to, net income or other financial measures calculated in accordance with GAAP. Non-GAAP adjusted earnings per share for the three and six month periods ended June 30, 2014 and guidance for the year ending December 31, 2014 are not based on any standardized methodology prescribed by GAAP and represents GAAP earnings per share adjusted to exclude (1) non-cash PDL royalty revenue, net of related costs, (2) non-cash interest expense on the liability related to the sale of future royalties and milestones to PDL, (3) amortization related to product acquisitions, and (4) stock-based compensation expense, and to adjust (5) the income tax provision to reflect the estimated amounts payable in cash. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP measures used by other companies. 

    The following table reconciles the Company's non-GAAP adjusted income/(loss) to GAAP net income for the three and six months ended June 30, 2014:  RECONCILIATION OF GAAP NET INCOME TO NON-GAAP ADJUSTED EARNINGS/(LOSS)(in thousands, except per share amounts)Three Months EndedJune 30, 2014GAAP net income


    12,746Non-cash PDL royalties, net of related costs(32,865)Non-cash interest expense on PDL liability4,903Amortization related to product acquisitions4,933Stock based compensation2,299Non-cash income tax adjustment8,300Non-GAAP adjusted earnings


    316Non-GAAP adjusted earnings per share


    0.01Six Months EndedJune 30, 2014GAAP net income


    30,684Non-cash PDL royalties, net of related costs(75,210)Non-cash interest expense on PDL liability10,282Amortization related to product acquisitions9,489Stock based compensation4,170Non-cash income tax adjustment20,128Non-GAAP adjusted (loss)


    (457)Non-GAAP adjusted (loss) per share



    The following table reconciles the Company's non-GAAP adjusted earnings per share guidance to GAAP earnings per share guidance for the year ending December 31, 2014:  RECONCILIATION OF GAAP EARNINGS PER SHARE TO NON-GAAP ADJUSTED EARNINGS PER SHAREGUIDANCE FOR THE YEAR ENDING DECEMBER 31, 2014GAAP earnings per share


     0.36 - 0.51 Non-cash PDL royalties, net of related costs (1.26 - 1.46) Non-cash interest expense on PDL liability 0.29 - 0.33 Amortization related to product acquisitions 0.27 - 0.29 Stock based compensation 0.12 - 0.14 Non-cash income tax adjustment 0.22 - 0.35 Non-GAAP adjusted earnings per share


     0.00 - 0.16 Conference CallDepomed will host a conference call today, Wednesday, August 6th, beginning at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its results.  Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a live webcast on the investor relations section of Depomed's website at   Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.

    About DepomedDepomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders.  Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. CAMBIA® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults.  Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and various partner product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology.
    Additional information about Depomed may be found at

    "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to the commercialization of Gralise, CAMBIA, Zipsor and Lazanda, Depomed's financial outlook for 2014 and expectations regarding financial results and potential business opportunities and other risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K for the year ended December 31, 2013 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2014 and June 30, 2014. The inclusion of forward-looking statements should not be regarded as a representation that any of the company's plans or objectives will be achieved. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

    August J. Moretti
    Depomed, Inc.

    Carolyn Hawley
    Canale Communications for Depomed

     CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (GAAP BASIS)(in thousands, except share and per share amounts)(Unaudited)Three Months Ended June 30,Six Months Ended June 30,2014201320142013Revenues:Product sales $




    23,235Royalties 43015,09792529,178License and other revenue 5,76076017,5203,724Non-cash PDL royalty revenue33,297-76,081-Total revenues 67,73229,963144,27756,137Costs and expenses:Cost of sales 4,6751,6888,3773,172Research and development expense 1,3971,4123,4394,710Selling, general and administrative expense32,57325,36865,09051,331Amortization of intangible assets2,5429635,0811,924Total costs and expenses 41,18729,43181,98761,137Income (loss) from operations 26,54553262,290(5,000)Other income (expense)(596)6(1,196)(41)Non-cash interest expense on PDL liability(4,903)-(10,282)-Benefit from (provision for) income taxes (8,300)(60)(20,128)39Net income (loss)$




    (5,002)Basic net income (loss) per share $




    (0.09)Diluted net income (loss) per  share $




    (0.09)Basic shares58,105,90256,562,43357,827,43056,511,911Diluted shares60,430,45657,142,34360,258,44556,511,911 CONSOLIDATED CONDENSED BALANCE SHEETS (GAAP BASIS)(in thousands)June 30,December 31,20142013(Unaudited)(1)Cash, cash equivalents and marketable securities



    276,017Accounts receivable17,27411,451Receivables from collaborative partners35,63510,824Inventories7,78210,145Property and equipment, net7,7318,340Intangible assets, net77,44082,521Deferred tax assets79,173103,202Prepaid and other assets7,3736,153Total assets



    508,653Accounts payable and accrued liabilities



    34,935Income taxes payable-61,875Deferred license revenue13,99515,516Liability related to sale of future royalties and milestones to PDL194,938233,981Other liabilities13,75213,666Contingent consideration liability12,19511,264Shareholders' equity179,326137,416Total liabilities and shareholders' equity 



    508,653(1)  Derived from the audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2013.

    SOURCE Depomed, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
    2. Depomed To Present At Jefferies 2012 Global Health Care Conference
    3. Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf
    4. Depomed To Present At JMP Securities 7th Annual Healthcare Conference
    5. Depomed To Report Second Quarter Fiscal Year 2012 Financial Results On Thursday, August 2, 2012
    6. Depomed To Present At Stifel Nicolaus 2012 Healthcare Conference
    7. Depomed To Present At Morgan Stanley 2012 Healthcare Conference
    8. Depomed To Present At UBS Global Life Sciences Conference
    9. Depomed To Report Third Quarter Fiscal Year 2012 Financial Results On Monday, November 5, 2012
    10. Depomed Reports Third Quarter Financial Results
    11. Depomed To Present At Lazard 2012 Healthcare Conference
    Post Your Comments:
    (Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
    (Date:10/7/2017)... IRVING, Texas , Oct. 6, 2017   ... industry with more than $100 billion in purchasing power, ... industry news and information. The Newsroom is ... chain and industry trends, infographics, expert bios, news releases, ... Besides having access to a wealth of resources at ...
    (Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare ... CPR training aide "cprCUBE" on Kickstarter. The device will ... during cardiac arrests with better efficiency compared to the ... offers real-time feedback on efficacy of the compression for ... campaign has a goal to raise $5,000. ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... WI (PRWEB) , ... October 13, 2017 , ... As ... in medicine known as “patient engagement.” The patient is doing more than filling out ... partners. , “There is an increasing emphasis in health care and research on ...
    (Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a ... utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the ... a CBD form that can be easily incorporated into liquid products, while reducing costs ...
    (Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
    (Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
    (Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
    Breaking Medicine News(10 mins):